Safety and tolerability of etravirine (ETR; TMC125) in hepatitis B and/or C co-infected patients in DUET-1 and DUET-2: pooled 48-week results
نویسندگان
چکیده
منابع مشابه
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
OBJECTIVES Human immunodeficiency virus (HIV)-infected patients are frequently co-infected with hepatitis B and/or C virus (HBV/HCV). The safety of etravirine was investigated over 96 weeks in patients co-infected with HIV type-1 (HIV-1) and HBV and/or HCV in the Phase III DUET trials. DUET-1 and DUET-2 are registered with clinicaltrials.gov (NCT00254046 and NCT00255099, respectively). METHOD...
متن کاملEfficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
BACKGROUND Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials. METHODS HIV type-1-infected treatment-experienced adults with viral loads >5,000 copies/ml and NN...
متن کاملOff-label use of antibiotics in hospitalized patients: focus on tigecycline.
790. et al. DUET-2: week-48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatment-experienced HIV-1-infected patients. In: Abstracts of the Fifteenth Conference on Abstract 791. et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized backgro...
متن کاملoccult hepatitis b in patients co-infected with hepatitis c and human immunodeficiency viruses
conclusions the significant number of coinfected hiv-hcv patients only had hbcab positive test without detectable hbv-dna. further studies for detection of hbv-dna in both serum and liver biopsy specimens may help clarify the impact of hbv infection in coinfected hiv/hcv patients. results of 103 hiv-hcv coinfected patients, both hbsag and hbcab were positive in 7 patients (6.8%), negative in 44...
متن کاملPooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
Results Overall virologic response rates at Week 48 were high (Figure 1).TMC278 showed non-inferior efficacy versus EFV. The impact of adherence, in addition to other factors, such as baseline viral load and exposure, on virologic response will be presented. Incidences of the following tolerability measures were significantly lower in the TMC278 group than in the EFV group: adverse events (AEs)...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the International AIDS Society
سال: 2008
ISSN: 1758-2652
DOI: 10.1186/1758-2652-11-s1-p272